Navigation Links
aTyr Pharma to Present at ChinaBio(R) Investor Forum in Hong Kong
Date:3/16/2009

Dr. James Cai, President of Hong Kong-based subsidiary Pangu BioPharma to Speak

SAN DIEGO, March 16 /PRNewswire/ -- aTyr Pharma, a privately held biopharmaceutical company focused on discovery and development of an entirely new class of natural protein therapeutics (biologics) for multiple disease indications, announced today that it will participate at the ChinaBio(R) Investor Forum in Hong Kong on 19 March 2009. Dr. James Cai, Senior Vice President of Clinical Development a aTyr Pharma and President of the Hong Kong based subsidiary Pangu BioPharma, will give an overview of aTyr's Discovery and Development program in the afternoon on Thursday, March 19th. The event will take place at the Hong Kong Science Park (http://www.chinabiollc.com/events/CBIF2009-HK/overview).

"aTyr Pharma and its Hong Kong subsidiary, Pangu BioPharma, are exactly the types of companies we seek out to present at our events," said Greg Scott, president and founder of ChinaBio LLC, organizer of the ChinaBio(R) Investor Forums. "aTyr's platform is strongly rooted in novel science, and Pangu is leveraging the best of China and Hong Kong through its research efforts here. We expect that aTyr will be very attractive to the over 50 VCs attending the Investor Forum."

aTyr has successfully raised Series A and Series B funds from leading U.S. based venture capital firms, including Alta Partners, Cardinal Partners and Polaris Venture Partners. In addition to supporting the company's continued platform discovery efforts, aTyr's management team is also preparing for preclinical development and Phase I studies for their first biologics drug candidate.

aTyr Pharma and Pangu BioPharma have a novel platform of naturally occurring protein fragments that can be developed into biologic agents for treating a wide variety of diseases. Capitalizing on the years of experience and discoveries made by founder Prof. Paul Schimmel, aTyr Pharma and Pangu BioPharma are identifying a broad platform of protein fragments derived from human aminoacyl tRNA synthetases. In his decades of research at MIT and now The Scripps Research Institute, Prof. Schimmel, has been a leader in discovering the many activities, roles and functions for this ancient class of enzymes and reported the first evidence that fragments and splice variants of these proteins have latent extracellular activities distinct from their intracellular roles in protein synthesis. With a wide variety of cell signaling activities, this class of unexplored peptides provides a reservoir of proteins with the potential to become blockbuster biotherapeutics ("Biologics").

Dr. Cai noted that "The ChinaBio Investors Forum provides a uniquely valuable platform for the leading biotech companies that are moving the China/Asia biotech community onto the global stage. It is a very motivating opportunity for me, helping investment groups identify the opportunity to share in the cutting edge of truly novel science while ultimately working towards better medicines for global patient populations."

About aTyr Pharma, Inc.

aTyr Pharma is a privately held biopharmaceutical company focused on identifying and developing a novel class of naturally occurring protein biologics for therapeutic application. aTyr's research facility is headquartered in San Diego, California, with offices in Hong Kong and Shanghai.

www.atyrpharma.com


'/>"/>
SOURCE aTyr Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
2. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
3. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
6. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
7. BioCis Pharma Starts Phase IIa Trial in Psoriasis
8. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
9. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results
10. Advance Nanotechs Owlstone Announces First Pharmaceutical Industry Order
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 18, 2017 , ... ... of Health (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading ... grant applications subject to the existing policy. AMIA recommended that NIH earmark funding ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter ... The tremendous growth is accounted to two main factors. The first is the ... network of vendors supplying FireflySci products all around the world. , 2016 was a ...
(Date:1/19/2017)... NEW YORK , Jan. 18, 2017 /PRNewswire/ ... expected to reach USD 92.9 billion by 2025, ... Research, Inc. Pharmaceutical industry has been adaptive of ... functions as early as 2002. Among the services ... the forerunners. For instance, Johnson & Johnson was ...
(Date:1/19/2017)... PLAINVIEW, N.Y. , Jan. 18, 2017 ... pathology services, announces the formation of an Executive Committee ... 2017 and beyond. John Cucci , ... been promoted from Director of Business Development to ... in 2015, Mr. Cucci served in senior sales leadership ...
Breaking Biology Technology:
(Date:1/11/2017)... 11, 2017  Michael Johnson, co-founder of Visikol Inc. a company ... has been named to the elite "Forbes 30 Under 30" list ... 600 people in 20 fields nationwide to be recognized as a ... applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
(Date:1/4/2017)...  CES 2017 – Valencell , the leading ... the launch of two new versions of its ... sensor modules that incorporate the best of Valencell,s ... The two new designs include Benchmark BE2.0, a ... Benchmark BW2.0, a 2-LED version of its original ...
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
Breaking Biology News(10 mins):